> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# OIG Report Examines ‘Misclassified’ Drugs in Rebate Program
- URL: https://www.fdaweb.com/oig-report-examines-misclassified-drugs-in-rebate-program/
- Published: 2018-01-03T12:00:00.000Z
- Updated: 2026-09-14T23:10:33.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5140403

A new HHS Office of Inspector General [report ](https://oig.hhs.gov/oei/reports/oei-03-17-00100.asp?ref=fdaweb.com)found that from 2012 to 2016 Medicaid may have lost $1.3 billion in base and inflation-adjusted rebates for 10 potentially-misclassified drugs with the highest total reimbursement in 2016\. “The vast majority of the approximately 30,000 drugs in the Medicaid rebate program were classified appropriately,” the report said. It recommended that HHS Centers for Medicare & Medicaid Services follow up with manufacturers associated with potentially misclassified drugs to determine whether current classifications are correct, and improve its drug data reporting for the Medicaid system to minimize inconsistent data submissions and track potential classification errors.